Pharmacological Research - Modern Chinese Medicine最新文献

{"title":"Comparative study of anti-inflammatory, antioxidant and antibacterial activities of epigallocatechin gallate, epigallocatechin, epicatechin gallate and epicatechin in vitro","authors":"Shuqi Wang ,&nbsp;Yu Chang ,&nbsp;Jingji Xu ,&nbsp;Chenru Zhao ,&nbsp;Yang Song ,&nbsp;Mingchun Liu ,&nbsp;Chunlian Tian","doi":"10.1016/j.prmcm.2025.100599","DOIUrl":"10.1016/j.prmcm.2025.100599","url":null,"abstract":"<div><h3>Introduction</h3><div>catechin compounds are flavanols substance from various natural plants, and play a significant part in anti-inflammatory, anti-tumor, anti-oxidation, anti-bacteria and protecting the heart and brain organs and other pharmacological effects, and widely found in traditional Chinese medicine, such as <em>Kadsurae Caulis</em> and <em>Reynoutria japonica</em> Houtt.</div></div><div><h3>Methods</h3><div>this research was focused on the comparative study of anti-inflammatory, antioxidant and antibacterial activities of (-)-epigallocatechin gallate, (-)-epigallocatechin, (-)-epicatechin gallate and (-)-epicatechin <em>in vitro</em>.</div></div><div><h3>Results</h3><div>the results indicated that the antioxidant activities of the four catechin compounds improved with the concentration increasing from 0.5 to 32 μg/ml, and the antibacterial activities of four catechins were stronger against the gram-positive bacteria (<em>Staphylococcus aureus</em> and <em>Arcanobacterium pyogenes</em>) than the gram-negative bacteria (<em>Escherichia coli</em> and <em>Salmonella</em>). Moreover, 12.5, 25 and 50 μmol/l of (-)-epicatechin, (-)-epigallocatechin gallate, and 6.25, 12.5 and 25 µmol/L of (-)-epigallocatechin, (-)-epicatechin gallate could reduce the content of NO and phagocytosis.</div></div><div><h3>Discussion</h3><div>these results laid a foundation for the research and development of natural anti-inflammatory, antioxidant and antibacterial drugs in food and pharmaceutical industries.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"15 ","pages":"Article 100599"},"PeriodicalIF":0.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-VEGF combined with fufang xueshuangtong versus anti-VEGF monotherapy for wet age-related macular degeneration: A meta-analysis","authors":"Tingke Xie ,&nbsp;Yanyan Lan ,&nbsp;Chengming Chen ,&nbsp;Jing Han","doi":"10.1016/j.prmcm.2025.100598","DOIUrl":"10.1016/j.prmcm.2025.100598","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the effectiveness and safety of combining anti-VEGF and fufang xueshuangtong in the treatment of wet age-related macular degeneration (wet AMD).</div></div><div><h3>Methods</h3><div>A systematic review of studies focusing on the efficacy and safety of the combined anti-VEGF and Fufang Xueshuantong therapy versus anti-VEGF monotherapy for wet AMD was conducted. This meta-analysis was performed based on a protocol registered in PROSPERO (CRD42024593135). The outcomes were reported as weighted mean differences (MDs) with corresponding 95 % confidence intervals (CI) or risk ratio (RR) with 95 % CI.</div></div><div><h3>Results</h3><div>A total of 9 studies, involving 731 participants, were included. The MD for best-corrected visual acuity (BCVA) improvement, central macular thickness (CMT), and size of choroidal neovascularization (CNV) between the combination therapy and monotherapy groups were 7.37 (95 % CI [5.35 to 9.39]), −35.57 (95 % CI [−47.02 to −24.12]), and −1.81 (95 % CI [−2.56 to −1.07]), respectively. Additionally, the combination therapy group showed greater improvement in serum and ocular hemodynamics and had a lesser impact on intraocular pressure, and there was no significant difference in the incidence of adverse reactions between the two regimens.</div></div><div><h3>Conclusions</h3><div>The combination of anti-VEGF therapy with Fufang Xueshuantong provides superior efficacy compared to anti-VEGF monotherapy in the treatment of wet AMD and is associated with an improved safety profile. However, further trials are needed to enhance the robustness and reliability of these findings.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"15 ","pages":"Article 100598"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143601061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Exploring the efficacy and mechanistic action of traditional Chinese medicine-derived phytochemicals in rheumatoid arthritis”","authors":"Uma Palanikumar ,&nbsp;Rajagopal Balasubramanian ,&nbsp;Prasanna Seenivasan ,&nbsp;Vellaikumar Sampathrajan ,&nbsp;Thangavelu AU","doi":"10.1016/j.prmcm.2025.100597","DOIUrl":"10.1016/j.prmcm.2025.100597","url":null,"abstract":"<div><h3>Introduction</h3><div>Rheumatoid arthritis [RA] is an autoimmune chronic inflammatory condition that leads to joint degeneration and functional disability. The most advanced pharmacological therapies that have been available for a long time remain limited, as they are associated with adverse effects and incomplete disease remission. In contrast, Traditional Chinese Medicine [TCM] is a promising alternative, as it utilizes phytochemicals obtained from medicinal plants.</div></div><div><h3>Methods</h3><div>This study explores the efficacy and mechanistic action of TCM-derived phytochemicals in the management of RA, with insights on <em>in silico</em> approaches, including molecular docking, ADME [Absorption, Distribution, Metabolism, and Excretion] studies, and network-based analysis using Cytoscape. We evaluated the interactions of flavonoids, alkaloids, terpenoids, and glycoside phytochemicals from key TCM plants with critical targets in RA, like pro-inflammatory cytokines [TNF-α, IL-1β], enzymes [COX-2, MMP-9], and signaling pathways [NF-κB, JAK/STAT], considering the applications of computational tools.</div></div><div><h3>Results</h3><div>The available evidence indicates that TCM phytochemicals modulate inflammation, inhibit key enzymes, and enhance anti-inflammatory responses for multi-target therapy of RA. <em>In silico</em> evidence of the efficacy and mechanistic actions is supportive of the promising therapeutic potential of TCM phytochemicals.</div></div><div><h3>Discussion</h3><div>Despite their numerous therapeutic advantages, phytochemicals also present certain limitations, such as poor oral bioavailability, off-target interactions, and manufacturing challenges. These factors necessitate significant structural modifications before their potential use as drugs. In addition, this study underscores the importance of further experimental and clinical validation.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"15 ","pages":"Article 100597"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-vitro & in-vivo efficacy of liposomal β-carryophyllene in ethylene glycol induced urolithiasis in rats","authors":"Ranjith Kumar R ,&nbsp;Suresh Janadri ,&nbsp;Manjunatha PM ,&nbsp;Madhu M V ,&nbsp;Rakshitha K B ,&nbsp;Preeti P Angadi ,&nbsp;Uday Raj Sharma ,&nbsp;Surrendra Vada ,&nbsp;Nageena Taj ,&nbsp;Jyotsna S Kharvi","doi":"10.1016/j.prmcm.2025.100587","DOIUrl":"10.1016/j.prmcm.2025.100587","url":null,"abstract":"<div><h3>Background</h3><div>Urolithiasis refers to the formation of stones in the urinary system. β-Caryophyllene, a bicyclic sesquiterpene found in herbs like cloves (Dīng Zǐ Xiāng), cinnamon (Ròu Guì), Black Pepper (Hú Jiāo) and Ginseng (Rén Shēn). Despite its potential, the antiurolithiatic activity of β-Caryophyllene, particularly in liposomal formulations, remains unexplored. This study aimed to evaluate the antiurolithiatic effects of liposomal β-Caryophyllene in ethylene glycol-induced urolithiasis in Wistar albino rats and elucidate its underlying mechanisms.</div></div><div><h3>Materials &amp; methods</h3><div><strong><em>IN-VITRO</em>:</strong> Using various in-vitro methods like aggregation, nucleation and titrimetric assay the percentage inhibition of calcium oxalate using the calcium chloride (Caox) and sodium oxalate solutions against the liposomal β-carryophyllene was performed for assessing anti-urolithiatic effect.</div><div><strong><em>IN-VIVO</em>:</strong> Ethylene glycol was used as the inducing agent. Albino rats were separated into 6 groups. Group-I named as normal diet. Group II-VI was given 0.75 % v/v EG was mixed in drinking water for causing renal stones, along with group III- V was treated with liposomal β-carryophyllene 100 mg/kg, 200 mg/kg and 400 mg/kg respectively. Group-VI was treated with standard drug, cystone (750 mg/kg).</div></div><div><h3>Results</h3><div>The study proved that liposomal β-caryophyllene (BCP) significantly inhibits calcium oxalate crystal formation, aggregation, and dissolution in both <em>in-vitro</em> and <em>in-vivo</em> models. BCP significantly reduced serum and urine markers of renal dysfunction and oxidative stress, with the highest dose (400 mg/kg) demonstrating effects similar to the standard drug (cystone).</div></div><div><h3>Conclusion</h3><div>Liposomal β-caryophyllene (BCP) shows promising therapeutic agent for urolithiasis, effectively preventing crystal formation and improving renal function. It demonstrated comparable efficacy to the standard treatment, suggesting its potential as a viable alternative or complementary therapy for managing urolithiasis.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100587"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143553002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traditional Chinese medicine Yiqi Huoxue Huatan recipe inhibits atherosclerosis by regulating intestinal flora and its associated metabolites","authors":"Hongtao Huang ,&nbsp;Wenqing Lv ,&nbsp;Hanjun Zhao ,&nbsp;Feiyue Xu ,&nbsp;Yu Huang","doi":"10.1016/j.prmcm.2025.100593","DOIUrl":"10.1016/j.prmcm.2025.100593","url":null,"abstract":"<div><h3>Background</h3><div>Yiqi Huoxue Huatan recipe (YHHR) has been shown to possess anti-atherosclerotic effects, as detailed in various studies and clinical observations. However, the potential mechanism underlying atherosclerosis remains unclear. This study aimed to verify the effects of YHHR on gut microbiota composition and plasma metabolite levels in atherosclerotic mice and its mechanism of action.</div></div><div><h3>Materials and Methods</h3><div>SPF apoE-/- mice were fed high-fat chow for 12 weeks to build an atherosclerosis model, Additionally, blank control group mice were fed normal chow, Mice were randomly assigned to the model group, low, medium and high dose YHHR group, antibiotic group and antibiotic + medium dose YHHR group. After three courses of drug administration, aortic plaques were observed by hematoxylin and eosin (HE) and Oil Red O staining, and mouse feces and serum were collected. The feces and serum of mice were analyzed using 16S rRNA sequencing, microbiological analysis, and targeted metabolomics. For cellular experiments, by constructing a foam cell model and applyingglycoursodeoxycholic acid(GUDCA)and Compound C interventions, WB was used to detect macrophage AMPK signaling pathway-related protein (AMPK) and efferocytosis-associated protein (ProS).</div></div><div><h3>Results</h3><div>YHHR was able to attenuate atherosclerotic plaque area, up-regulate the levels of gut bacteria <em>Akkermansia muciniphila (A. muciniphila)</em> and gut bacteria-associated metabolite bile acids GUDCA, and promote macrophage efferocytosis through the AMPK signaling pathway to exert anti-AS effects.</div></div><div><h3>Conclusion</h3><div>YHHR may play a role in preventing atherosclerosis by influencing the production of the intestinal flora and its associated metabolites.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100593"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143509296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tanyu Tongzhi decoction ameliorates atherosclerosis by inhibiting trimethylamine N-oxide-induced vascular inflammation via PI3K/Akt/NF-κB pathway regulation","authors":"Yingying Li ,&nbsp;Haonan Wu ,&nbsp;Ruoqi Li ,&nbsp;Wenjing Zong ,&nbsp;Xiang Li ,&nbsp;Huamin Zhang ,&nbsp;Danli Tang","doi":"10.1016/j.prmcm.2025.100582","DOIUrl":"10.1016/j.prmcm.2025.100582","url":null,"abstract":"<div><h3>Introduction</h3><div>Tanyu Tongzhi decoction (TYTZD) is an orally administered traditional Chinese medicine formula that is used to treat atherosclerosis (AS). Trimethylamine N-oxide (TMAO), a gut microbial metabolite, has been shown to accelerate AS development and progression. Despite its various health benefits, it is unclear whether TYTZD can ameliorate TMAO-mediated vascular inflammation. Therefore, we investigated the effect and molecular mechanisms of TYTZD in TMAO-induced vascular inflammation during AS progression.</div></div><div><h3>Methods</h3><div>Key ingredients of TYTZD were detected using high-performance liquid chromatography (HPLC). Additionally, we established an AS model by feeding <em>ApoE^-/-</em> mice high-fat and high-choline diet (HFCD). We examined the anti-AS effects of TYTZD using histological assay, immunohistochemical staining, and western blotting. Furthermore, we examined the effect of TYTZD on the viability of human umbilical vein endothelial cells (HUVECs) treated with TMAO using CCK-8 assay.</div></div><div><h3>Results</h3><div><em>In vivo</em> experiment showed that TYTZD treatment ameliorated AS by preventing dyslipidemia, reducing lipid deposition area in the intimal plaque, inhibiting arterial inflammation, and suppressing serum levels of TMA and TMAO in <em>ApoE^-/-</em> mice. Additionally, TYTZD significantly inhibited TMAO-induced endothelial activation, suppressed the expression of pro-inflammatory factors (IL-1β, IL-6, IL-8, TNF-α and MCP-1), and downregulated PI3K, Akt, and NF-κB protein expression in HUVECs.</div></div><div><h3>Conclusions</h3><div>TYTZD ameliorates AS by inhibiting TMAO-induced vascular inflammation via the PI3K/Akt/NF-κB signaling pathway; these findings highlight its potential application for the treatment of AS and associated disorders.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100582"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143520609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the efficacy and mechanism of Qingxuan decoction in treating opioid-induced constipation","authors":"Yarong Zhang ,&nbsp;Haoshi Cao ,&nbsp;Linling Su ,&nbsp;Xianxia Yuan ,&nbsp;Ling Mo ,&nbsp;Wenyu Jiang ,&nbsp;Xiaoli Feng ,&nbsp;Dongling Liu ,&nbsp;Yang Hai","doi":"10.1016/j.prmcm.2025.100592","DOIUrl":"10.1016/j.prmcm.2025.100592","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to investigate the formulation of Qing Xuan Decoction (QXD) and its possible mechanism of action in the treatment of opioid-induced constipation (OIC).</div></div><div><h3>Methods</h3><div>We used orthogonal design experiments to optimize the decoction and ethanol precipitation process for QXD. The efficacy of QXD on loperamide - induced constipation in mice was explored via intestinal motility assay and defecation study. We examined the influence of QXD on the intestinal microbiota of mice through 16S rRNA sequencing. We assessed the alterations in the H₂O₂ and superoxide anion scavenging rates in serum using commercial kits.</div></div><div><h3>Results</h3><div>The optimal decoction protocol for QXD entails boiling it with a 10 - fold volume of water for three consecutive cycles, each lasting 1.5 h. The optimized ethanol precipitation process requires using 85 % ethanol and performing the procedure three times, with each instance of precipitation lasting over 48 h. QXD enhanced small intestine propulsion rate and defecation efficacy, significantly ameliorating loperamide-induced constipation. QXD increased the abundance of Bacteroides, Prevotella, and Akkermansia in the intestine, decreased the abundance of Desulfovibrio, and kept the intestinal flora balanced. QXD mitigated oxidative stress by decreasing H₂O₂ levels and augmenting superoxide anion scavenging ability.</div></div><div><h3>Conclusion</h3><div>QXD is expected to be a promising therapeutic drug for OIC, and its mechanism of action may be to alleviate constipation by regulating the homeostasis of intestinal flora while reducing oxidative stress.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100592"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143529134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy studies of nine Chinese traditional patent medicines for the treatment of post-myocardial infarction heart failure: A Bayesian network","authors":"Fuyun Jia ,&nbsp;Shengwei Gao ,&nbsp;Qiaochu Zhu ,&nbsp;Opoku Bonsu Francis ,&nbsp;Rui Liu ,&nbsp;Yadong Wang ,&nbsp;Rui Zhang ,&nbsp;Shichuan Chen ,&nbsp;Zilian Zhan ,&nbsp;Xi Zhang ,&nbsp;Qiang Xu","doi":"10.1016/j.prmcm.2025.100595","DOIUrl":"10.1016/j.prmcm.2025.100595","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of 64 million people globally. After many years of use and development, Traditional Chinese Medicine (TCM) has accumulated rich clinical usefulness in many diseases. This network meta-analysis aimed to assess the effectiveness of nine different Chinese traditional patent medicines (CTPMs) in the treatment of heart failure developing after acute myocardial infarction.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Determine the eligibility criteria for inclusion and exclusion in advance. Starting from literature search until September 20, 2024, conduct comprehensive data retrieval on 7 different databases. Network plots, league tables, surface-under-the-cumulative ranking (SUCRA), and funnel plots were created for each outcome. A previous registration (PROSPERO CRD42024519394) of this review protocol was undertaken.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 56 eligible RCTs involving 5,567 patients with heart failure secondary to acute myocardial infarction in which nine CTPMs were used as treatment are included. The CTPMs included &lt;em&gt;Qili Qiangxin&lt;/em&gt; capsule (QLQXC), Compound &lt;em&gt;Danshen Dripping&lt;/em&gt; Pills (CDDP), &lt;em&gt;Shexiang Baoxin&lt;/em&gt; pill (SXBXP), Stilbene &lt;em&gt;yiqi&lt;/em&gt; dropping refs (SYQDR), &lt;em&gt;Xintong&lt;/em&gt; oral liquid (XTOL), &lt;em&gt;Wenxin&lt;/em&gt; granule (WXG), &lt;em&gt;Tongxinluo&lt;/em&gt; capsule (TXLC), and &lt;em&gt;Guanxinshutong&lt;/em&gt; capsule (GXSTC) and &lt;em&gt;Huangqibaoxin&lt;/em&gt; particle (HQBXP). The experimental group received CTPM therapy in addition to conventional Western medicine (CWM) treatment, whereas the control group received just CWM treatment. The results showed that compared to those treated with CWM alone, those treated with CPTM + CWM considerably improved in all relevant measures. When evaluating clinical effectiveness based on left ventricular end-diastolic diameter and the New York Heart Association's (NYHA) cardiac functional classification, WXG + CWM was shown to be the most successful in enhancing cardiac efficiency. The 6-minute walking test results were most improved by SXBXP + CWM, but N-terminal pro-brain natriuretic peptide reduction, left ventricular ejection percent, and left ventricular end-systolic diameter were best achieved by XTOL + CWM. When compared to the other combination treatments, the QLQXC + CWM therapy was the most successful in increasing left ventricular end-diastolic volume while the GXSTC + CWM treatment was the most successful in increasing left ventricular end-systolic volume. There were no appreciable variations in safety between the groups treated with CWM alone and the ones treated with CTPMs plus CWM.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;div&gt;In contrast to CWM therapy alone, the combination of CTPMs and CWM treatment offers greater therapeutic benefits and is safe for treating heart failure that follows an acute myocardial infarction. For heart failure that develops after an acute myocard","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100595"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143509295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wuzang Wenyang Huayu Tang Treatment of vascular dementia by modulation of BCL-2/BAX/Caspase3: An integrated in vitro cellular assay and network pharmacological analysis","authors":"Yu-Cheng Lu ,&nbsp;Yu-Fu Zeng ,&nbsp;Yan-Chun Li ,&nbsp;Chun-Mei Liang ,&nbsp;Ying-Ying Cao ,&nbsp;Ling Zhang ,&nbsp;Meng-Qi Li ,&nbsp;Jia-Jia Zhong ,&nbsp;Li-Mei Liang","doi":"10.1016/j.prmcm.2025.100591","DOIUrl":"10.1016/j.prmcm.2025.100591","url":null,"abstract":"<div><h3>Objective</h3><div>This project explores Wuzang Wenyang Huayu Tang (WWHT) 's potential mechanisms for treating vascular dementia (VD) based on network pharmacology and experimental validation.</div></div><div><h3>Methods</h3><div>TCMSP was used to screen the active ingredients and targets of WWHT; GeneCards was used to identify VD-related targets; Cytoscape 3.10.0 was used to generate an \"active ingredient-target\" network map; STRING and Cytoscape were used to generate a PPI network map; Metascape and WeiShengxin performed GO and KEGG analysis to screen potential signaling pathways and explore the mechanisms; cell experiments were performed to verify the relevant targets.</div></div><div><h3>Results</h3><div>117 active components of WWHT were screened, and 146 gene targets intersected with VD. The high-frequency nodes in the PPI network include CASP3, MMP9, BCL2, etc. GO analysis showed that the biological functions involved hormones, nitrogen compounds, and other responses; KEGG analysis revealed that the pathways were concentrated in the signaling pathways such as AGE-RAGE, MAPK, etc. To treat VD, WWHT may enhance HT22 morphology in ischemia-hypoxia, control apoptosis-related proteins, and promote HT22 proliferation.</div></div><div><h3>Conclusion</h3><div>As a means to effectively treat VD, WWHT may protect neuronal cells, regulate cell apoptosis, and reduce brain damage by using a multi-component, multi-target, and multi-pathway strategy.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"15 ","pages":"Article 100591"},"PeriodicalIF":0.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143580698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential and mechanisms of puerarin in liver disease: A comprehensive review of pharmacological effects and drug delivery innovations","authors":"Lokeshvar Ravikumar ,&nbsp;Ramaiyan Velmurugan ,&nbsp;J Sam Helinto ,&nbsp;S Yokesh ,&nbsp;B Divya ,&nbsp;Harshitha GS ,&nbsp;Harish Kanna S ,&nbsp;Mahalakshmi Devaraji","doi":"10.1016/j.prmcm.2025.100594","DOIUrl":"10.1016/j.prmcm.2025.100594","url":null,"abstract":"<div><h3>Background</h3><div>Pueraria, a renowned traditional Chinese herb, has been valued for both medicinal and culinary uses. Puerarin, its primary bioactive compound, exhibits a diverse pharmacological profile and has garnered attention for its hepatoprotective properties. This review explores puerarin's potential in managing liver diseases, including hepatic malignancy, alcohol-associated liver disease, and metabolic dysfunction-associated steatotic liver disease.</div></div><div><h3>Methods</h3><div>An extensive literature review was conducted, analyzing studies that examine puerarin's effects on liver disease pathways. Emphasis was placed on its mechanisms involving lipid metabolism regulation, oxidative stress reduction, autophagy induction, and inflammation modulation. The review also evaluates novel drug delivery techniques designed to enhance puerarin's bioavailability, given its limited solubility.</div></div><div><h3>Results</h3><div>Puerarin demonstrates therapeutic efficacy across various liver diseases by targeting key biochemical pathways. Studies show it effectively modulates lipid levels, reduces oxidative stress, induces autophagy, and decreases inflammation. Recent advances in drug delivery have significantly improved puerarin's bioavailability, enhancing its clinical application potential.</div></div><div><h3>Discussion and Conclusion</h3><div>Puerarin holds promise as a safe, low-toxicity treatment for liver diseases, backed by favourable pharmacological activity and clinical trial data. Its hepatoprotective actions are further strengthened through innovative drug delivery methods, highlighting puerarin's viability in therapeutic applications. Continued research is recommended to further understand its mechanisms and optimize delivery strategies. Puerarin's unique pharmacological profile positions it as a potential therapeutic agent for liver disease management.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100594"},"PeriodicalIF":0.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143464574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}